Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $327,629.04. Following the completion of the sale, the chief executive officer now owns 125,022 shares of the company's stock, valued at $5,991,054.24. This represents a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Christopher Peetz also recently made the following trade(s):
- On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98.
Mirum Pharmaceuticals Price Performance
MIRM traded up $0.95 on Monday, hitting $48.48. 1,319,360 shares of the company's stock traded hands, compared to its average volume of 540,941. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -24.00 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $49.40. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The company's 50 day simple moving average is $43.76 and its 200-day simple moving average is $41.61.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's revenue for the quarter was up 89.4% on a year-over-year basis. During the same period last year, the company earned ($0.57) EPS. As a group, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current year.
Analyst Ratings Changes
MIRM has been the topic of several research analyst reports. Citigroup increased their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. HC Wainwright restated a "buy" rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners upped their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Finally, Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $57.10.
Read Our Latest Stock Report on MIRM
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the business. Golden State Equity Partners raised its holdings in shares of Mirum Pharmaceuticals by 1,390.8% in the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company's stock worth $801,000 after buying an additional 18,080 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company's stock valued at $421,000 after acquiring an additional 1,003 shares during the last quarter. R Squared Ltd purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth $69,000. Secure Asset Management LLC lifted its position in shares of Mirum Pharmaceuticals by 9.3% during the fourth quarter. Secure Asset Management LLC now owns 39,920 shares of the company's stock worth $1,651,000 after purchasing an additional 3,406 shares during the last quarter. Finally, Avanza Fonder AB purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at $189,000.
About Mirum Pharmaceuticals
(
Get Free Report)
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mirum Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mirum Pharmaceuticals wasn't on the list.
While Mirum Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.